Wall Street Analysts Predict a 38.95% Upside in Enovis (ENOV): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis Corporation (ENOV) Q3 2024 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Xuyang Li - Jefferies Jeff Johnson - Baird Brandon Vazquez - William Blair Caitlin Cronin - Canaccord Danielle Antalffy - UBS Mike Matson - Needham & Company Operator Good day, and welcome to the Enovis Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.56 per share a year ago.
Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says
JMP Securities initiated coverage on Enovis Corporation ENOV, a medical technology company focusing on orthopedics.
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Enovis (ENOV) Q2 Earnings Top Estimates
Enovis (ENOV) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.61 per share a year ago.
Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Enovis Languishing Despite Respectable Performance
Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot compete long term with rivals that offer robotic systems (and implants designed for those robotic systems). Robotic system competition is indeed a threat, particularly if robotic systems move into shoulder surgeries in a big way, but Enovis has a strong competitive position in the ambulatory segment.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
